Followers | 4054 |
Posts | 152159 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
Tuesday, April 11, 2017 8:33:07 AM
GlobeNewswire-April 11, 2017
-- Milestone payment received with completion of IND-enabling toxicology studies --
-- Catalyst’s collaborator, ISU Abxis, plans to initiate a Phase 1/2 proof-of-concept study in individuals with severe hemophilia B in the second quarter of 2017 --
SOUTH SAN FRANCISCO, Calif., April 11, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc., (CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it has achieved a key milestone under its collaboration with ISU Abxis to advance the Factor IX program towards its first human clinical trial. Completion of the CB 2679d/ISU304 toxicology studies supported the recent Investigational New Drug (IND) approval by the Korean Ministry of Food and Drug Safety (MFDS) and triggered a milestone payment to Catalyst.
CB 2679d/ISU304, a highly potent next-generation coagulation Factor IX variant, has demonstrated the potential to normalize human Factor IX levels with a daily subcutaneous injection in preclinical studies. Currently approved therapies rely on frequent intravenous infusions where adherence is difficult and convenient access to peripheral veins is a problem, often requiring the use of central venous access devices with the associated risks of infection and thrombosis. Catalyst’s collaborator, ISU Abxis (086890.KQ), plans to initiate a Phase 1/2 proof-of-concept study with single and multiple subcutaneous injections in individuals with severe hemophilia B in the second quarter of 2017.
“Individuals with severe hemophilia B will experience abnormal bleeding - not just after an injury, but spontaneously into potentially any organ, joints or muscles. Without preventative treatment or prophylaxis, these individuals may experience several spontaneous bleeding episodes per month,” said Nassim Usman, Ph.D., President and Chief Executive Officer of Catalyst. “Our vision is to prevent bleeding with the stabilization and normalization of clotting levels using more convenient subcutaneous dosing.”
Catalyst has a collaboration with ISU Abxis to advance the development of CB 2679d/ISU304 through a Phase 1/2 proof-of-concept study in individuals with severe hemophilia B. After Phase 1/2, ISU Abxis has an option for exclusive commercial rights in South Korea and a profit share on ex-South Korean commercialization. Catalyst retains full development and commercial rights for CB 2679d/ISU304 outside of South Korea. Under the license agreement, the next potential milestone payment is for the first patient enrolled in the Phase 1/2 trial.
About Factor IX
CB 2679d/ISU304 is a next-generation coagulation Factor IX variant that is IND-approved in South Korea. Catalyst believes that CB 2679d/ISU304 may allow for subcutaneous prophylactic treatment of individuals with hemophilia B. Learn more about Factor IX.
About Hemophilia and Factor Replacement Therapy
Hemophilia, for which there is no cure, is a rare but serious bleeding disorder that results from a genetic or an acquired deficiency of a protein required for normal blood coagulation. Individuals with hemophilia suffer from spontaneous bleeding episodes as well as substantially prolonged bleeding times upon injury. Learn more about hemophilia.
About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
Recent CBIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2024 01:13:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2024 01:10:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2024 01:07:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2024 01:05:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2024 01:01:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2024 12:58:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2024 12:56:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2024 12:53:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2024 12:50:24 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:05:32 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:23:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:14:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/18/2024 08:31:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 08:27:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/16/2024 08:03:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/15/2024 09:19:53 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 07/12/2024 08:42:48 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 07/12/2024 08:41:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2024 08:45:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/03/2024 05:18:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/02/2024 09:11:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/01/2024 10:00:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/01/2024 09:56:30 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM